Aspire Biopharma Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $1,003,904 | $3,633 |
| Prepaid expenses and other current assets | 55,102 | 144,356 |
| Inventories | 253,160 | - |
| Total current assets | 1,312,166 | 147,989 |
| TOTAL ASSETS | $1,312,166 | $147,989 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $1,014,377 | $310,219 |
| Accrued expenses | 1,008,569 | - |
| Due to affiliate | 353,679 | - |
| Notes payable – related party | 885,564 | 1,266,832 |
| Promissory note fee – related party | 1,000,000 | - |
| Other current liabilities | - | 111,026 |
| Derivative liability | 40,954 | - |
| Loan and transfer notes payable – related party | 499,214 | - |
| Subscription agreement loans | 1,500,000 | - |
| Convertible note | 1,290,476 | - |
| Total current liabilities | 7,592,833 | 1,688,077 |
| Forward purchase agreement liability | 95,662 | - |
| TOTAL LIABILITIES | 7,688,495 | 1,688,077 |
| COMMITMENTS AND CONTINGENCIES (Note 9) | - | - |
| STOCKHOLDERS’ DEFICIT | ||
| Preferred Stock; $0.0001 par value, 10,000,000 shares authorized, none issued or outstanding | - | - |
| Common stock; $0.0001 par value; 490,000,000 shares authorized; 3,533,408 and 690,044 issued and outstanding at December 31, 2025 and 2024, respectively | 353 | 69 |
| Additional paid-in capital | 20,881,399 | 1,237,076 |
| Accumulated deficit | (27,258,081) | (2,777,233) |
| TOTAL STOCKHOLDERS’ DEFICIT | (6,376,329) | (1,540,088) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $1,312,166 | $147,989 |
The Company’s common stock shares issued and outstanding, common stock and additional paid-in capital as of December 31, 2025 and 2024 have been retroactively restated for the reverse stock split as described in Note 3 of the accompanying notes, which are an integral part of these consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.